摘要
目的观察尿激酶联合低分子肝素钙治疗急性心肌梗死的临床效果。方法将我院收治的急性心肌梗死患者40例随机分为治疗组和对照组,各20例。治疗组给予尿激酶联合低分子肝素钙治疗,对照组单独给予尿激酶治疗,均连续治疗5～7d,比较两组患者临床效果。结果治疗组血管再通率为100%,对照组血管再通率为72%,两组比较差异有统计学意义(P<0.05);经过一段时间的溶栓治疗后,治疗组出血率为10%,对照组出血率为35%,两组出血率比较,差异有统计学意义(P<0.05)。结论尿激酶联合低分子肝素钙治疗急性心肌梗死的临床效果较好,是安全有效的溶栓药物,值得临床推广应用。
Objective To observe the effect of urokinase combined with low molecular heparin calcium in the treatment of acute myocardial infarction clinical effect.Methods In our hospital,40 cases of acute myocardial infarction were randomly divided into treatment group and control group,20 cases in each.The treatment group were treated with urokinase combined with low molecular heparin calcium in the treatment of control group treated with urokinase,alone,were continuously treated for 5~7d,compared two groups of patients with clinical effect.Results The treatment group recanalization rate was 100%;the control group recanalization rate was 72%,there was significant difference between two groups（P〈0.05）;after a period of time after thrombolytic therapy,the treatment group bleeding rate for 10%,controls bleeding rate for 35%,two sets of bleeding rate comparison,the difference was statistically significance（P〈0.05）.Conclusion Urokinase combined with low molecular heparin calcium in the treatment of acute myocardial infarction clinical effect is good,is safe and effective thrombolytic drugs,worthy of clinical application.
出处
《实用心脑肺血管病杂志》
2012年第11期1802-1803,共2页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
尿纤溶酶原激活物
肝素
低分子量
心肌梗死
治疗结果
Urinary plasminogen activator
Heparin,low-molecular-weight
Myocardial infarction
Treatment outcome
